WHO ICTRP trial
adIVO
CTIS2024-520219-42-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2024-520219-42-00 |
|---|---|
| Public title | adIVO |
| Scientific title | adIVO – A phase II trial of ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma - adIVO |
| Primary sponsor | Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No |
| Countries | Germany |
| Conditions | ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma;Therapeutic area: Diseases [C] - Digestive System Diseases [C06];Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Tibsovo 250 mg film-coated tablets, Product Code:PRD10392230, Pharmaceutical Form: FILM-COATED TABLET, Other descriptive name: , Strength: |
| Registration date | May 6, 2025 |
| Target size | 40 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: